Pediatrix Medical Group Inc (NYSE: MD) has seen a decline in its stock price by -2.48 in relation to its previous close of 9.28. However, the company has experienced a 2.03% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-07 that The headline numbers for Pediatrix Medical Group (MD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Is It Worth Investing in Pediatrix Medical Group Inc (NYSE: MD) Right Now?
Company’s 36-month beta value is 1.59.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 10 as “hold,” and 1 as “sell.”
The public float for MD is 83.32M, and currently, short sellers hold a 5.52% ratio of that floaft. The average trading volume of MD on May 08, 2024 was 691.81K shares.
MD’s Market Performance
The stock of Pediatrix Medical Group Inc (MD) has seen a 2.03% increase in the past week, with a -4.84% drop in the past month, and a -0.55% fall in the past quarter. The volatility ratio for the week is 5.13%, and the volatility levels for the past 30 days are at 3.60% for MD. The simple moving average for the past 20 days is -0.96% for MD’s stock, with a -15.57% simple moving average for the past 200 days.
Analysts’ Opinion of MD
Many brokerage firms have already submitted their reports for MD stocks, with SVB Leerink repeating the rating for MD by listing it as a “Mkt Perform.” The predicted price for MD in the upcoming period, according to SVB Leerink is $29 based on the research report published on September 27, 2021 of the previous year 2021.
Stifel, on the other hand, stated in their research note that they expect to see MD reach a price target of $30. The rating they have provided for MD stocks is “Hold” according to the report published on June 23rd, 2021.
Deutsche Bank gave a rating of “Sell” to MD, setting the target price at $12 in the report published on October 19th of the previous year.
MD Trading at -1.81% from the 50-Day Moving Average
After a stumble in the market that brought MD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.75% of loss for the given period.
Volatility was left at 3.60%, however, over the last 30 days, the volatility rate increased by 5.13%, as shares sank -5.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.80% upper at present.
During the last 5 trading sessions, MD rose by +2.03%, which changed the moving average for the period of 200-days by -35.95% in comparison to the 20-day moving average, which settled at $9.11. In addition, Pediatrix Medical Group Inc saw -2.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MD starting from Swift James D, who sale 5,764 shares at the price of $9.58 back on Dec 14 ’23. After this action, Swift James D now owns 90,874 shares of Pediatrix Medical Group Inc, valued at $55,219 using the latest closing price.
Moore Mary Ann E, the EVP, General Counsel & Sec of Pediatrix Medical Group Inc, sale 1,150 shares at $9.62 during a trade that took place back on Dec 14 ’23, which means that Moore Mary Ann E is holding 15,730 shares at $11,063 based on the most recent closing price.
Stock Fundamentals for MD
Current profitability levels for the company are sitting at:
- -0.0 for the present operating margin
- 0.21 for the gross margin
The net margin for Pediatrix Medical Group Inc stands at -0.02. The total capital return value is set at -0.0. Equity return is now at value -6.94, with -2.65 for asset returns.
Based on Pediatrix Medical Group Inc (MD), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at 0.15. The debt to equity ratio resting at 0.91. The interest coverage ratio of the stock is -20.2.
Currently, EBITDA for the company is 196.08 million with net debt to EBITDA at 5.36. When we switch over and look at the enterprise to sales, we see a ratio of 0.77. The receivables turnover for the company is 7.04for trailing twelve months and the total asset turnover is 0.92. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.38.
Conclusion
In a nutshell, Pediatrix Medical Group Inc (MD) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
